Success Metrics

Clinical Success Rate
100.0%

Based on 44 completed trials

Completion Rate
100%(44/44)
Active Trials
0(0%)
Results Posted
64%(28 trials)

Phase Distribution

Ph phase_2
6
13%
Ph phase_3
5
11%
Ph phase_4
28
60%
Ph phase_1
4
9%

Phase Distribution

4

Early Stage

6

Mid Stage

33

Late Stage

Phase Distribution43 total trials
Phase 1Safety & dosage
4(9.3%)
Phase 2Efficacy & side effects
6(14.0%)
Phase 3Large-scale testing
5(11.6%)
Phase 4Post-market surveillance
28(65.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

93.6%

44 of 47 finished

Non-Completion Rate

6.4%

3 ended early

Currently Active

0

trials recruiting

Total Trials

47

all time

Status Distribution
Completed(44)
Terminated(3)

Detailed Status

Completed44
Withdrawn3

Development Timeline

Analytics

Development Status

Total Trials
47
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (9.3%)
Phase 26 (14.0%)
Phase 35 (11.6%)
Phase 428 (65.1%)

Trials by Status

withdrawn36%
completed4494%

Recent Activity

Clinical Trials (47)

Showing 20 of 47 trialsScroll for more
NCT01519960Phase 3

A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B

Completed
NCT01088659Phase 3

A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.

Completed
NCT01429792Phase 4

A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)

Completed
NCT00087633Phase 4

PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.

Completed
NCT01033448Phase 4

A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response

Completed
NCT00922207Phase 4

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B

Completed
NCT00487747Phase 4

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B.

Completed
NCT01179594Phase 4

A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B.

Withdrawn
NCT01185860Phase 1

A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1

Completed
NCT00940420Phase 4

A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis C

Completed
NCT01903954Phase 2

A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C

Completed
NCT01057667Phase 2

A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4

Completed
NCT01296971Phase 3

A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)

Withdrawn
NCT01337375Phase 1

A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination Therapy

Completed
NCT01591460Phase 4

A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C

Completed
NCT01086085Phase 4

A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive

Completed
NCT01237496Phase 3

Analysis of HBV-Specific Immune Response in Patients With HBeAg Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a (40KD)) - Immunology Sub-Study of ML18253

Completed
NCT00614471Phase 4

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.

Completed
NCT01278134Phase 2

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)

Completed
NCT01579019Phase 2

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment

Withdrawn

Drug Details

Intervention Type
DRUG
Total Trials
47